NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the fourth quarter and the year ended December 31, 2010. Celldex reported net income of $22.7 million, or $0.71 basic earnings per share, and $0.70 fully diluted earnings per share for the fourth quarter of 2010 compared to a net loss of $12.9 million, or ($0.41) per basic and diluted share, for the fourth quarter of 2009. Net income for the fourth quarter of 2010 includes one-time items totaling $30.5 million for rindopepimut (CDX-110) related revenue recorded as a result of the termination of the Pfizer license agreement and a charge to royalty expense related to costs originally capitalized in connection with the Pfizer license agreement. Celldex regained rights to rindopepimut during the fourth quarter of 2010.
